Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients

Brain, Behavior, and Immunity

Volumn 25, Issue 8, 2011, Pages 1576-1581

  Myint, A M ^a,b   Schwarz, M J ^b   Verkerk, R ^c   Mueller, H H ^b   Zach, J ^b   Scharpe S ^c   Steinbusch, H W M ^a   Leonard, B E ^a,b   Kim, Y K ^d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Korea University   (South Korea)

Author keywords

3 Hydroxykynurenine; Antipsychotics; Kynurenic acid; Kynurenine; Schizophrenia

Indexed keywords

3 HYDROXYKYNURENINE; AMISULPRIDE; ARIPIPRAZOLE; KYNURENIC ACID; OLANZAPINE; RISPERIDONE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; ALGORITHMS; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; PATIENT DISCHARGE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SPECTROPHOTOMETRY, ULTRAVIOLET; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 80053900888     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.05.005     Document Type: Article

References (52)

1. Diagnostic and statistical manual of mental disorders 1994, APA, American Psychiatric Press, Washington, DC. fourth ed.
2. Arolt V., Rothermundt M., Wandinger K.P., Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol. Psychiatry 2000, 5:150-158.
3. Avgustin B., Wraber B., Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat. Med. J. 2005, 46:268-274.
4. Bender D.A., Mccreanor G.M. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem. Soc. Trans. 1985, 13:441-443.
5. Blennow K., Davidsson P., Gottfries C.G., Ekman R., Heilig M. Synaptic degeneration in thalamus in schizophrenia. Lancet 1996, 348:692-693.
6. Byne W., Kidkardnee S., Tatusov A., Yiannoulos G., Buchsbaum M.S., Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr. Res. 2006, 85:245-253.
7. Byne W., Fernandes J., Haroutunian V., Huacon D., Kidkardnee S., Kim J., Tatusov A., Thakur U., Yiannoulos G. Reduction of right medial pulvinar volume and neuron number in schizophrenia. Schizophr. Res. 2007, 90:71-75.
8. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J. Leukoc. Biol. 1989, 45:29-34.
9. Ceresoli-Borroni G., Rassoulpour A., Wu H.Q., Guidetti P., Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J. Neural. Trans. 2006, 113:1355-1365.
10. Chiarugi A., Calvani M., Meli E., Traggiai E., Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 2001, 120:190-198.
11. Condray R., Dougherty G.G., Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., Matson W.R., Mcevoy J., Kaddurah-Daouk R., Yao J.K. Roxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 2011, 1:12.
12. Doorduin J., De Vries E.F., Willemsen A.T., De Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50:1801-1807.
13. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10:59-76.
14. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 2001, 313:96-98.
15. First M., Spitzer R.L., Gibbon M., William J.B. Structured clinical Interview for DSM-IV Axis I Disorder - Patient Edition (SCID-I/P, version 2.0), Biometrics Research Department, New York 1998, State Psychiatric Institute, New York.
16. Gal E., Sherman A.D. l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 1980, 5:223-239.
17. Hervé C., Beyne P., Jamault H., Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr. B Biomed. Appl. 1996, 675:157-161.
18. Heyes M.P., Saito K., Major E.O., Milstien S., Markey S.P., Vickers J.H. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from l-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993, 116(Pt 6):1425-1450.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
20. Kim J.P., Choi D.W. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 1987, 23:423-432.
21. KIM Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., Leonard B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1129-1134.
22. Kim Y.K., Lee K.M., Choi H.S., Jang H.S., Lee B.H., HAN C.S. A study on the reliability and validity of the Korean version of the Calgary depression scale for schizophrenia (K-CDSS). J. Korean Neuropsychiatr. Assoc. 2005, 44:446-455.
23. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
24. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol. Today 1999, 20:469-473.
25. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 1073-1074:25-37.
26. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006, 10:131-148.
27. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98:143-151.
28. Nilsson L.K., Linderholm K.R., Engberg G., Paulson L., Blennow K., Lindstrom L.H., Nordin C., Karanti A., Persson P., Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 2005, 80:315-322.
29. Oades R.D., Dauvermann M.R., Schimmelmann B.G., Schwarz M.J., Myint A.M. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication. Behav. Brain Funct. 2010, 6:29.
30. Oades R.D., Myint A.M., Dauvermann M.R., Schimmelmann B.G., Schwarz M.J. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav. Brain Funct. 2010, 6:32.
31. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 1998, 70:299-307.
32. Olney J.W., Farber N.B. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J. Clin. Psychiatry 1994, 55(Suppl. B):43-46.
33. Olney J.W., Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995, 13:335-345.
34. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33:523-533.
35. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., Lee S.J., Lee C., Paik I.H. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int. Immunopharmacol. 2006, 6:666-671.
36. Perez-Neri I., Ramirez-Bermudez J., Montes S., Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006, 31:1279-1294.
37. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982, 247:184-187.
38. Price S.A., Rose D.P., Toseland P.A. Effects of dietary vitamin B 6 deficiency and oral contraceptives on the spontaneous urinary excretion of 3-hydroxyanthranilic acid. Am. J. Clin. Nutr. 1972, 25:494-498.
39. Ravikumar A., Deepadevi K.V., Arun P., Manojkumar V., Kurup P.A. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol. India 2000, 48:231-238.
40. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 1998, 37:186-193.
41. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
42. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 2001, 50:521-530.
43. Schwarz M.J., Chiang S., Muller N., Ackenheil M. T-Helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 2001, 15:340-370.
44. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001, 56:483-486.
45. Schwieler L., Erhardt S. Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology 2003, 28:1770-1777.
46. Seok Jeong B., Kwon J.S., Yoon Kim S., Lee C., Youn T., Moon C.H., Yoon Kim C. Functional imaging evidence of the relationship between recurrent psychotic episodes and neurodegenerative course in schizophrenia. Psychiatry Res. 2005, 139:219-228.
47. Shepard P.D., Joy B., Clerkin L., Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003, 28:1454-1462.
48. Sperner-Unterweger B., Whitworth A., Kemmler G., Hilbe W., Thaler J., Weiss G., Fleischhacker W.W. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res. 1999, 38:61-70.
49. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
50. Theberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Williamson P.C. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 2007, 191:325-334.
51. Yao J.K., Dougherty G.G., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., Rozen S., Krishnan R.R., Mcevoy J., Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry 2010, 15:938-953.
52. Yasui H., Takai K., Yoshida R., Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2, 3-dioxygenase: its possible occurrence in cancer patients. Proc. Natl. Acad. Sci. USA 1986, 83:6622-6626.